We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca’s oncology portfolio put on another good show, with anti-PD-L1 Imfinzi and Merck & Co.-shared PARP inhibitor Lynparza now on track to cross the blockbuster line for the first time in 2019.